Monday, June 05, 2023
BiondVax Pharmaceuticals announced that it has signed an exclusive worldwide licence agreement to develop and commercialise VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for various indications, starting with psoriasis and psoriatic arthritis. This collaboration involves the Max Planck Society and the University Medical Centre Gottingen (UMG).
Indeed, the licence agreement between BiondVax Pharmaceuticals and Max Planck for the IL-17 NanoAb represents an exciting opportunity for the development of a unique treatment for psoriasis and other autoimmune diseases. This collaboration serves as a validation of the productive relationship between BiondVax, Max Planck, and UMG, highlighting the potential for further significant developments in the future.
The BiondVax-MPG-UMG research collaboration agreement outlines rigorous criteria that NanoAb candidates must meet before being in-licenced by BiondVax. These criteria include factors such as binding affinity, neutralisation of the target, and other relevant attributes. By setting high standards for the NanoAb candidates, the collaboration aims to ensure the development of effective and promising treatments.
